tetano
Editor, Senior Moderator
J Med Virol
. 2022 Dec 29.
doi: 10.1002/jmv.28443. Online ahead of print.
Early administration of Paxlovid reduces the viral elimination time in patients infected with SARS-CoV-2 omicron variants
Yu Wang[SUP] 1 [/SUP], Danyang Zhao[SUP] 2 [/SUP], Xinbing Liu[SUP] 1 [/SUP], Xubo Chen[SUP] 3 [/SUP], Wenying Xiao[SUP] 1 [/SUP], Liuliu Feng[SUP] 1 [/SUP]
Affiliations
Abstract
Nirmatrelvir/ritonavir (Paxlovid) is an oral antiviral drug that has been shown to reduce the risk of hospitalization, severe COVID-19 and mortality among mild-to-moderate COVID-19 patients who are at risk of developing severe disease This article is protected by copyright. All rights reserved.
Keywords: Antiviral agents; Infection; SARS coronavirus; Virus classification.
. 2022 Dec 29.
doi: 10.1002/jmv.28443. Online ahead of print.
Early administration of Paxlovid reduces the viral elimination time in patients infected with SARS-CoV-2 omicron variants
Yu Wang[SUP] 1 [/SUP], Danyang Zhao[SUP] 2 [/SUP], Xinbing Liu[SUP] 1 [/SUP], Xubo Chen[SUP] 3 [/SUP], Wenying Xiao[SUP] 1 [/SUP], Liuliu Feng[SUP] 1 [/SUP]
Affiliations
- PMID: 36579782
- DOI: 10.1002/jmv.28443
Abstract
Nirmatrelvir/ritonavir (Paxlovid) is an oral antiviral drug that has been shown to reduce the risk of hospitalization, severe COVID-19 and mortality among mild-to-moderate COVID-19 patients who are at risk of developing severe disease This article is protected by copyright. All rights reserved.
Keywords: Antiviral agents; Infection; SARS coronavirus; Virus classification.